198 related articles for article (PubMed ID: 31727504)
1. Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes.
Federizon J; Frye A; Huang WC; Hart TM; He X; Beltran C; Marcinkiewicz AL; Mainprize IL; Wills MKB; Lin YP; Lovell JF
Vaccine; 2020 Jan; 38(4):942-950. PubMed ID: 31727504
[TBL] [Abstract][Full Text] [Related]
2. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
3. Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development.
Izac JR; Oliver LD; Earnhart CG; Marconi RT
Vaccine; 2017 May; 35(24):3178-3185. PubMed ID: 28479174
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA
PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146
[TBL] [Abstract][Full Text] [Related]
5. Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice.
Meirelles Richer L; Aroso M; Contente-Cuomo T; Ivanova L; Gomes-Solecki M
Clin Vaccine Immunol; 2011 Nov; 18(11):1809-16. PubMed ID: 21918116
[TBL] [Abstract][Full Text] [Related]
6. Design and development of a novel vaccine for protection against Lyme borreliosis.
Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U
PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015
[TBL] [Abstract][Full Text] [Related]
7. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
Scheckelhoff MR; Telford SR; Hu LT
Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
[TBL] [Abstract][Full Text] [Related]
8. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
9. A study with a commercial vaccine against Lyme borreliosis in horses using two different vaccination schedules: Characterization of the humoral immune response.
Knödlseder JM; Fell SF; Straubinger RK
Vaccine; 2019 Nov; 37(49):7207-7212. PubMed ID: 31635975
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
Klouwens MJ; Salverda MLM; Trentelman JJ; Ersoz JI; Wagemakers A; Gerritzen MJH; van der Ley PA; Hovius JW
Vaccine; 2021 Apr; 39(18):2561-2567. PubMed ID: 33812741
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies.
Kurtenbach K; Dizij A; Voet P; Hauser P; Simon MM
Vaccine; 1997 Oct; 15(15):1670-4. PubMed ID: 9364698
[TBL] [Abstract][Full Text] [Related]
12. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
[TBL] [Abstract][Full Text] [Related]
14. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.
LaFleur RL; Dant JC; Wasmoen TL; Callister SM; Jobe DA; Lovrich SD; Warner TF; Abdelmagid O; Schell RF
Clin Vaccine Immunol; 2009 Feb; 16(2):253-9. PubMed ID: 19052162
[TBL] [Abstract][Full Text] [Related]
15. A brief history of OspA vaccines including their impact on diagnostic testing for Lyme disease.
Wormser GP
Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115572. PubMed ID: 34763193
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi.
Conlon JA; Mather TN; Tanner P; Gallo G; Jacobson RH
Vet Ther; 2000; 1(2):96-107. PubMed ID: 19757556
[TBL] [Abstract][Full Text] [Related]
17. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Venezuelan Equine Encephalitis (VEE) replicon-based Outer surface protein A (OspA) vaccines in a tick challenge mouse model of Lyme disease.
Gipson CL; Davis NL; Johnston RE; de Silva AM
Vaccine; 2003 Sep; 21(25-26):3875-84. PubMed ID: 12922122
[TBL] [Abstract][Full Text] [Related]
19. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
20. Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.
Munson EL; Du Chateau BK; Jobe DA; Lovrich SD; Callister SM; Schell RF
Infect Immun; 2000 Oct; 68(10):5496-501. PubMed ID: 10992445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
